'''Lymphatic vessel endothelial hyaluronan receptor 1''' ('''LYVE1'''), also known as '''extracellular link domain containing 1''' ('''XLKD1''') is a [[Link domain]]-containing [[hyaladherin]], a protein capable of binding to [[hyaluronic acid]] (HA), homologous to [[CD44]], the main HA receptor.<ref>{{cite journal|last1=Banerji|first1=Suneale|last2=Ni|first2=Jian|last3=Wang|first3=Shu-Xia|last4=Clasper|first4=Steven|last5=Su|first5=Jeffrey|last6=Tammi|first6=Raija|last7=Jones|first7=Margaret|last8=Jackson|first8=David G.|title=LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan|journal=The Journal of Cell Biology|date=22 February 1999|volume=144|issue=4|pages=789–801|doi=10.1083/jcb.144.4.789|pmid=10037799|pmc=2132933}}</ref> In humans it is encoded by the ''LYVE1'' gene.<ref name="entrez">{{cite web | title = Entrez Gene: XLKD1 extracellular link domain containing 1| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10894| accessdate = }}</ref>
'''Lymphatic vessel endothelial hyaluronan receptor 1''' ('''LYVE1'''), also known as '''extracellular link domain containing 1''' ('''XLKD1''') is a [[Link domain]]-containing [[hyaladherin]], a protein capable of binding to [[hyaluronic acid]] (HA), homologous to [[CD44]], the main HA receptor.<ref>{{cite journal|last1=Banerji|first1=Suneale|last2=Ni|first2=Jian|last3=Wang|first3=Shu-Xia|last4=Clasper|first4=Steven|last5=Su|first5=Jeffrey|last6=Tammi|first6=Raija|last7=Jones|first7=Margaret|last8=Jackson|first8=David G.|title=LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan|journal=The Journal of Cell Biology|date=22 February 1999|volume=144|issue=4|pages=789–801|doi=10.1083/jcb.144.4.789|pmid=10037799|pmc=2132933}}</ref> In humans it is encoded by the ''LYVE1'' gene.<ref name="entrez">{{cite web | title = LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 [ Homo sapiens (human) ]| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10894| accessdate = }}</ref>
LYVE1 is a type I integral membrane [[glycoprotein]]. It acts as a receptor and binds to both soluble and immobilized hyaluronan. This protein may function in lymphatic hyaluronan transport and have a role in tumor metastasis.<ref name="entrez"/> LYVE-1 is a cell surface receptor on [[Lymphatic endothelium|lymphatic endothelial cells]] that can be used as a lymphatic endothelial cell marker, allowing for the [[Cell sorting|isolation]] of these cells for experimental purposes. The physiological role for this receptor is still the subject of debate, but evolutionary conservation suggests an important role.
LYVE1 is a type I integral membrane [[glycoprotein]]. It acts as a receptor and binds to both soluble and immobilized hyaluronan. This protein may function in lymphatic hyaluronan transport and have a role in tumor metastasis.<ref name="entrez"/> LYVE-1 is a cell surface receptor on [[Lymphatic endothelium|lymphatic endothelial cells]] that can be used as a lymphatic endothelial cell marker, allowing for the [[Cell sorting|isolation]] of these cells for experimental purposes. The physiological role for this receptor is still the subject of debate, but evolutionary conservation suggests an important role.
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), also known as extracellular link domain containing 1 (XLKD1) is a Link domain-containing hyaladherin, a protein capable of binding to hyaluronic acid (HA), homologous to CD44, the main HA receptor.[1] In humans it is encoded by the LYVE1 gene.[2]
LYVE1 is a type I integral membrane glycoprotein. It acts as a receptor and binds to both soluble and immobilized hyaluronan. This protein may function in lymphatic hyaluronan transport and have a role in tumor metastasis.[2] LYVE-1 is a cell surface receptor on lymphatic endothelial cells that can be used as a lymphatic endothelial cell marker, allowing for the isolation of these cells for experimental purposes. The physiological role for this receptor is still the subject of debate, but evolutionary conservation suggests an important role.
Jackson DG (2003). "The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1". Trends Cardiovasc. Med. 13 (1): 1–7. doi:10.1016/S1050-1738(02)00189-5. PMID12554094.
Cunnick GH, Jiang WG, Gomez KF, Mansel RE (2001). "Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model". Biochem. Biophys. Res. Commun. 288 (4): 1043–6. doi:10.1006/bbrc.2001.5869. PMID11689016.
Mouta Carreira C, Nasser SM, di Tomaso E, et al. (2001). "LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis". Cancer Res. 61 (22): 8079–84. PMID11719431.
Cursiefen C, Schlötzer-Schrehardt U, Küchle M, et al. (2002). "Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin". Invest. Ophthalmol. Vis. Sci. 43 (7): 2127–35. PMID12091407.
Otsuki T, Ota T, Nishikawa T, et al. (2007). "Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries". DNA Res. 12 (2): 117–26. doi:10.1093/dnares/12.2.117. PMID16303743.
Nguyen VA, Kutzner H, Fürhapter C, et al. (2006). "Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence". Mod. Pathol. 19 (2): 291–8. doi:10.1038/modpathol.3800537. PMID16424896.
Llovet JM, Chen Y, Wurmbach E, et al. (2007). "A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis". Gastroenterology. 131 (6): 1758–67. doi:10.1053/j.gastro.2006.09.014. PMID17087938.
